LevelJump Announces Grant of Stock Options
Toronto, Ontario--(Newsfile Corp. - February 26, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) ("Leveljump" or the "Company") announces that, pursuant to the Company's 2022 Equity Incentive Plan, it has granted an aggregate of 2,250,000 incentive stock options (the "Options") to three directors of the Company. Each Option entitles the optionee to acquire one common share of the Company at an exercise price of $0.065 per common share until February 24, 2031. There are no vesting restrictions
Soins de santé et hôpitaux, Santé
2026-02-26 8:00 AM EST | LevelJump Healthcare Corp.
HEALWELL AI Expands Global Footprint with First AI Implementation in Middle East and Growing Enterprise Adoption Across Canada and the United States
HEALWELL has signed its first contract to deliver AI solutions in the Middle East to a major governmental health system, marking a key step in its global expansion. This new deployment to an existing Orion Health customer demonstrates the scalability of the DARWEN™ platform and reinforces the Company's commitment to improving patient care worldwide. HEALWELL is deploying SMART Identify, SMART Search, and SMART Summary across healthcare systems in Canada and the U.S., improv
Technologies, Soins de santé et hôpitaux
2026-02-26 3:15 AM EST | HEALWELL AI
FY25 Results: Resilient Performance with Strong Profit Gains in Challenging Markets
Baar, Switzerland--(Newsfile Corp. - February 26, 2026) - Ad hoc announcement pursuant to Art. 53 LR MEDIA RELEASE Ad hoc announcement pursuant to Art. 53 LR Full-Year 2025 Results
Technologies, Construction / bâtiments, Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques
2026-02-26 12:09 AM EST | medmix AG
CareRx Corporation to Host Annual and Fourth Quarter 2025 Financial Results Conference Call on Thursday, March 5, 2026 at 8:30 a.m. ET
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company") today announced it will host a conference call to discuss its annual and fourth quarter 2025 financial results on Thursday, March 5, 2026, at 8:30 a.m. Eastern Time (ET). The Company expects to report its annual and fourth quarter 2025 financial results for the period ended December 31, 2025, after market close on Wednesday, March 4, 2026. Telephone Dial-
2026-02-25 7:30 AM EST | CareRx Corporation
Scryb Reports Positive Q1 2026: Cash Increased 50%, Liabilities Down 27%, Remains Largest Shareholder of Cybeats
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company") announces that it has filed its audited consolidated financial statements and Management's Discussion and Analysis for the fiscal quarter ended December 31, 2025 ("Q1 2026"). The filings are available on SEDAR+. Q1 2026 Highlights Cash position improved by 50% to $1.2 million (from $0.8 million at September 30, 2025), with working capital rising 6
Biotechnologies, Soins de santé et hôpitaux, Santé
2026-02-25 7:01 AM EST | NorthPalm Capital Corp.
Adia Med of Winter Park Expands into Cosmetics Due to High Patient Demand - Now Interviewing Nurse Practitioners for Hair Growth and Aesthetic Procedures
Winter Park, Florida--(Newsfile Corp. - February 24, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and innovative wellness solutions through its subsidiary Adia Med, today announced that its Winter Park clinic is actively interviewing candidates for a Nurse Practitioner position specializing in cosmetic treatments, including advanced hair growth therapies.
Soins de santé et hôpitaux, Santé
2026-02-24 8:30 AM EST | Adia Nutrition Inc.
Envoy Medical Regains Compliance with Nasdaq Listing Requirement
White Bear Lake, Minnesota--(Newsfile Corp. - February 24, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) through the alternatives permitted under Listing Rule 5550(b). As previously disclosed
Biotechnologies, Soins de santé et hôpitaux
2026-02-24 8:00 AM EST | Envoy Medical, Inc.
Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space
White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of three new patents with one in the United States and two in Hong Kong, further expanding its intellectual property and reinforcing its competitive position in the cochlear implant industry. "We believe the future of the cochlear implant industry
Biotechnologies, Soins de santé et hôpitaux
2026-02-23 8:00 AM EST | Envoy Medical, Inc.
Jones Healthcare Group Wins Best of Show and Best in Class Honours at PAC Global Awards for Qube(TM) Eco
London, Ontario--(Newsfile Corp. - February 20, 2026) - As healthcare systems face increasing pressure to reduce waste and carbon impact, packaging innovation must deliver measurable results without compromising patient safety or pharmacy workflow. At the same time, environmental claims across industries are under greater scrutiny, with regulators, retailers and consumers demanding proof over promise. At the 2026 PAC Global Awards ceremony, held February 18-19 in Toronto, Jones Healthca
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-02-20 12:36 PM EST | Jones Healthcare Group
Apolo V Acquisition Corp. Amendment to Definitive Agreement with TelyRx, Inc. and Rescheduling of Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Apolo V Acquisition Corp. (TSXV: AFV.P) ("Apolo V" or the "Company") announces it has amended its business combination agreement with TelyRx, Inc. ("TelyRx") dated January 19, 2026 (the "Business Combination Agreement") effected in connection with its previously announced proposed qualifying transaction (the "Qualifying Transaction") and postponed its special meeting of shareholders (the "Meeting
Soins de santé et hôpitaux, Santé
2026-02-20 12:10 PM EST | TelyRx
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of canc
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-02-20 7:00 AM EST | Theralase Technologies Inc.
Greer Consulting Expands Internationally to Support Employers in Building Resilient, Engaged Workforces Across North America and the UAE
New York, New York--(Newsfile Corp. - February 19, 2026) - Greer Consulting, Inc. ("GCI" or the "Company"), a trusted leader in workforce and labor relations advisory, is pleased to announce that it has formally expanded its practice internationally, with a new consulting partnership in Dubai, United Arab Emirates. GCI recently completed a significant engagement with a multinational employer in the UAE undergoing a challenging workforce transition involving heightened empl
Technologies, Soins de santé et hôpitaux, Machinerie, Logement
2026-02-19 8:00 AM EST | Greer Consulting Inc.
Envoy Medical Provides Business Update Following Transformative Financing and Positive Progress in Clinical Trial
Financing was led by new investor and top-tier healthcare fund Nantahala Capital and longtime Envoy Medical shareholder, billionaire Glen Taylor Closing of $30 million in gross proceeds in upsized offering, with up to an additional $48 Million upon exercise of milestone warrants, provides potential funding through commercialization Company hosting Fireside Chat with Dr. Theodore
Biotechnologies, Soins de santé et hôpitaux
2026-02-19 8:00 AM EST | Envoy Medical, Inc.
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - February 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-02-19 7:00 AM EST | Phio Pharmaceuticals Corp.
HEALWELL AI and WELL Health Launch WELLTRUST to Empower Patients and Accelerate AI Powered Ethical Patient Identification for Clinical Research
HEALWELL and WELL launch WELLTRUST™, a consent-first data governance and patient-identification platform enabling secure, compliant and scalable clinics data mobilization across WELL-operated clinics. WELLTRUST provides patients with clear, flexible, and revocable control over consent, while enabling researchers and clinicians to identify appropriate patients in an ethical, privacy-first way. The first commercial application combines WELL's expansive clinical footpr
Technologies, Soins de santé et hôpitaux
2026-02-19 3:15 AM EST | HEALWELL AI
Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement
Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2.8 million shares-for-interest private placement with an immediate family member (the "Subscriber") of Resverlogix's Chairman and CEO. Under the terms of the shares-for-interest transaction, the Subscriber subscribed for 28,000,000 common shares at CAD$0.10 per share for aggregate proceeds of CAD$2.8 million. After giving effect to the trans
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-02-18 7:00 PM EST | Resverlogix Corp.
Discovery Senior Living to Honor Team Members from Across the Nation at 2026 Pillars of Excellence Awards in Dallas
Bonita Springs, Florida--(Newsfile Corp. - February 18, 2026) - Discovery Senior Living ("Discovery" or the "Company") and its affiliated subsidiaries, one of the most trusted and the largest privately held senior housing operators in the U.S., will bring together team members from across the country this week in Dallas for its annual Pillars of Excellence Awards, a premier celebration honoring the individuals and communities who exemplify the Company's mission and values every day.
Soins de santé et hôpitaux, Immobilier, Logement
2026-02-18 3:16 PM EST | Discovery Senior Living
Relief AI Inc. Congratulates Johannes "Hansi" Lochner on Historic Gold Medal Victory at the Milano, Cortina Italy Olympics
Toronto, Ontario--(Newsfile Corp. - February 18, 2026) - Relief AI Inc. (the "Company "or "Relief AI Inc.") (www.reliefai.ca), Relief AI Inc. proudly congratulates German bobsleigh champion Johannes Lochner on capturing the gold medal at the Milano, Cortina Italy Olympics, leading a historic podium sweep for Germany with gold, silver, and bronze in the 2 man bobsleigh event, a remarkable display of excellence
Technologies, Soins de santé et hôpitaux, Santé
2026-02-18 10:05 AM EST | Relief AI Inc.
Cosmo to Participate in Upcoming Investor Conferences
Dublin, Ireland--(Newsfile Corp. - February 18, 2026) - Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce its participation in the following upcoming investor conferences: UBS European Healthcare Conference 2026 London, United Kingdom 4 March 2026 Svetlana Sigalova, Chief Financial Officer, will participate in one-on-one meetings with investors.
Soins de santé et hôpitaux, Santé
2026-02-18 1:01 AM EST | Cosmo Pharmaceuticals N.V.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2026, the three months ended December 31, 2025 ("Third Quarter"). Consolidated revenues for the three-month period ending December 31, 2025, were $31.6 million, an increase of $17.2 million or approximately 120% as compared
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-02-17 4:19 PM EST | Elite Pharmaceuticals, Inc.